SmithKline LYMErix Dosing Studies For Earlier Efficacy Urged By FDA Cmte.

SmithKline Beecham should conduct a dosing study of its LYMErix vaccine to see if immunity to Lyme disease can be established more quickly than with the proposed three-dose/one-year schedule, FDA's Vaccines & Related Biological Products Advisory Committee agreed at a meeting May 26.